ECM
ALDX icon

Endurant Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Endurant Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,576
Closed -$213K – 53
2019
Q1 		$213K Sell
23,576
-43,063
-65% -$366K 0.08% 69
2018
Q4 		$553K Sell
66,639
-3,361
-5% -$34.4K 0.29% 45
2018
Q3 		$966K Buy
+70,000
New +$568K 0.43% 48

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's ALDX Position: Q2 2019 in Review

Endurant Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2019, closing a stake of 23,576 shares — an estimated $213K sold.

Endurant Capital Management first reported a position in ALDX in Q3 2018 and held it in 3 quarters. The position peaked at $966K in Q3 2018. 76 funds tracked by Wall St. Rank hold ALDX as of Q2 2019.

  • Endurant Capital Management reported no remaining Aldeyra Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Endurant Capital Management sold 23,576 Aldeyra Therapeutics shares in Q2 2019, an estimated $213K.
  • Endurant Capital Management first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 3 quarters.
  • Endurant Capital Management's Aldeyra Therapeutics position peaked at $966K in Q3 2018.
  • 76 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.